Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.
作者信息
Traer E, MacKenzie R, Snead J, Agarwal A, Eiring A M, O'Hare T, Druker B J, Deininger M W
出版信息
Leukemia. 2012 May;26(5):1140-3. doi: 10.1038/leu.2011.325. Epub 2011 Nov 18.
Abstract
摘要
相似文献
1
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.阻断JAK2介导的外在生存信号可恢复慢性粒细胞白血病细胞对ABL抑制剂的敏感性。
Leukemia. 2012 May;26(5):1140-3. doi: 10.1038/leu.2011.325. Epub 2011 Nov 18.
2
Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells.姜黄素诱导 K562 白血病细胞中 BCR-ABL/JAK/STAT 通路下调和凋亡。
Asian Pac J Cancer Prev. 2021 Dec 1;22(12):3959-3965. doi: 10.31557/APJCP.2021.22.12.3959.
3
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.选择性JAK2/ABL双重抑制疗法可有效清除对酪氨酸激酶抑制剂（TKI）不敏感的慢性粒细胞白血病干细胞/祖细胞。
Oncotarget. 2014 Sep 30;5(18):8637-50. doi: 10.18632/oncotarget.2353.
4
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.ABL激酶抑制剂伊马替尼与Janus激酶2抑制剂TG101348联合用于靶向残留的BCR-ABL阳性细胞。
J Hematol Oncol. 2014 Apr 28;7:37. doi: 10.1186/1756-8722-7-37.
5
Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.Jak2 1型抑制剂NVP-BSK805和NVP-BVB808对Jak2突变阳性和Bcr-Abl阳性细胞系的作用。
Acta Haematol. 2014;132(1):75-86. doi: 10.1159/000356784. Epub 2014 Jan 31.
6
ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis.ABL特异性酪氨酸激酶抑制剂STI571在体外对Ph阳性急性淋巴细胞白血病和急变期慢性粒细胞白血病有效。
Leukemia. 2001 Jun;15(6):989-90. doi: 10.1038/sj.leu.2402137.
7
SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.SKI-606是一种Src和Abl激酶的4-苯胺基-3-喹啉腈双重抑制剂，是一种对培养中的慢性粒细胞白血病细胞具有强效抗增殖作用的药物，并能使裸鼠体内的K562异种移植瘤消退。
Cancer Res. 2003 Jan 15;63(2):375-81.
8
miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.微小RNA-101通过下调Jak2和抑制核因子κB靶基因使K562细胞系对伊马替尼敏感。
Tumour Biol. 2016 Oct;37(10):14117-14128. doi: 10.1007/s13277-016-5205-9. Epub 2016 Aug 12.
9
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.BCR-ABL 使慢性髓性白血病中的经典 JAK2-STAT5 信号脱偶联。
Nat Chem Biol. 2012 Jan 29;8(3):285-93. doi: 10.1038/nchembio.775.
10
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.PP2A 激活剂药物选择性根除 TKI 耐药性慢性髓性白血病干细胞。
J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.
引用本文的文献
1
Novel treatment strategies for chronic myeloid leukemia.慢性髓性白血病的新型治疗策略
Blood. 2025 Feb 27;145(9):931-943. doi: 10.1182/blood.2024026312.
2
The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance.基于底物的激酶抑制剂改善靶点选择性和克服耐药性的前景。
Chem Sci. 2024 Jul 13;15(33):13130-13147. doi: 10.1039/d4sc01088d. eCollection 2024 Aug 22.
3
The Role of Cytokines in Activation of Tumour-promoting Pathways and Emergence of Cancer Drug Resistance.细胞因子在肿瘤促进途径激活及癌症耐药性产生中的作用
Curr Top Med Chem. 2024;24(6):523-540. doi: 10.2174/0115680266284527240118041129.
4
CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26).CXCR2抑制通过PI3K/Akt/mTOR和二肽基肽酶Ⅳ（CD26）消除慢性髓性白血病干细胞，从而克服波纳替尼不耐受。
Heliyon. 2023 Nov 9;9(11):e22091. doi: 10.1016/j.heliyon.2023.e22091. eCollection 2023 Nov.
5
Induction of DNMT1-dependent demethylation of SHP-1 by the natural flavonoid compound Baicalein overcame Imatinib-resistance in CML CD34 cells.诱导 SHP-1 的 DNMT1 依赖性去甲基化通过天然黄酮类化合物黄芩素克服 CML CD34 细胞中的伊马替尼耐药性。
Cell Commun Signal. 2023 Mar 3;21(1):47. doi: 10.1186/s12964-023-01049-9.
6
Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis.卡非佐米增强芦可替尼在骨髓纤维化中的抑制作用。
Cancers (Basel). 2021 Sep 28;13(19):4863. doi: 10.3390/cancers13194863.
7
Combinatorial Strategies to Target Molecular and Signaling Pathways to Disarm Cancer Stem Cells.靶向分子和信号通路以消除癌症干细胞的组合策略。
Front Oncol. 2021 Jul 26;11:689131. doi: 10.3389/fonc.2021.689131. eCollection 2021.
8
Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia.隐丹参酮通过抑制慢性髓性白血病中的 STAT3 和 eIF4E 信号通路增强 Bcr-Abl 酪氨酸激酶抑制剂的疗效。
Pharm Biol. 2021 Dec;59(1):893-903. doi: 10.1080/13880209.2021.1944224.
9
Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?靶向慢性髓性白血病中的白血病干细胞：值得努力吗？
Int J Mol Sci. 2021 Jun 30;22(13):7093. doi: 10.3390/ijms22137093.
10
Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation.慢性髓性白血病联合疗法实现潜在无治疗缓解：聚焦白血病干细胞与免疫调节
Front Oncol. 2021 May 13;11:643382. doi: 10.3389/fonc.2021.643382. eCollection 2021.
本文引用的文献
1
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.尽管抑制了 BCR-ABL 活性，但人类慢性髓系白血病干细胞对伊马替尼不敏感。
J Clin Invest. 2011 Jan;121(1):396-409. doi: 10.1172/JCI35721. Epub 2010 Dec 13.
2
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.至少持续 2 年完全分子缓解的慢性髓性白血病患者停止伊马替尼治疗：前瞻性、多中心停止伊马替尼（STIM）试验。
Lancet Oncol. 2010 Nov;11(11):1029-35. doi: 10.1016/S1470-2045(10)70233-3. Epub 2010 Oct 19.
3
Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).Jak2/Abl激酶抑制剂ON044580破坏Bcr-Abl/Jak2网络可克服急变期慢性髓性白血病（CML）的耐药性。
Genes Cancer. 2010 Apr;1(4):346-59. doi: 10.1177/1947601910372232.
4
Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.阻断细胞因子信号及强烈抑制 Bcr-Abl 激酶可诱导慢性髓系白血病祖细胞凋亡。
Leukemia. 2010 Apr;24(4):771-8. doi: 10.1038/leu.2009.299. Epub 2010 Feb 4.
5
The leukemic stem cell niche: current concepts and therapeutic opportunities.白血病干细胞微环境：当前概念与治疗机遇
Blood. 2009 Aug 6;114(6):1150-7. doi: 10.1182/blood-2009-01-202606. Epub 2009 Apr 28.
6
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.CYT387，一种选择性JAK1/JAK2抑制剂：激酶选择性的体外评估以及使用真性红细胞增多症患者的细胞系和原代细胞进行的临床前研究。
Leukemia. 2009 Aug;23(8):1441-5. doi: 10.1038/leu.2009.50. Epub 2009 Mar 19.
7
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.在药物耐药性的骨髓微环境模型中，Stat3促成对BCR-ABL抑制剂的耐药性。
Mol Cancer Ther. 2008 Oct;7(10):3169-75. doi: 10.1158/1535-7163.MCT-08-0314.
8
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.基质介导的对酪氨酸激酶抑制剂治疗的表达BCR-ABL的白血病细胞的保护作用。
Mol Cancer Ther. 2008 May;7(5):1121-9. doi: 10.1158/1535-7163.MCT-07-2331. Epub 2008 Apr 29.
9
Hematopoietic cytokine receptor signaling.造血细胞因子受体信号传导
Oncogene. 2007 Oct 15;26(47):6724-37. doi: 10.1038/sj.onc.1210757.
10
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.TG101209，一种小分子JAK2选择性激酶抑制剂，能有效抑制与骨髓增殖性疾病相关的JAK2V617F和MPLW515L/K突变。
Leukemia. 2007 Aug;21(8):1658-68. doi: 10.1038/sj.leu.2404750. Epub 2007 May 31.
Zotero 插件